Humanized and chimeric monoclonal antibodies to CD47
Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
1. An isolated chimeric or humanized antibody that specifically binds to human CD47 comprising a variable heavy (VH) region containing the VH complementarity regions, CDR1, CDR2 and CDR3, respectively set forth in SEQ ID NO: 20, 20 and 22; and a variable light (VL) region containing the VL complementarity regions, CDR1, CDR2 and CDR3, respectively set forth in SEQ ID NO:23, 24 and 25.
2. The antibody of claim 1 , wherein said variable light (VL) region comprises the amino acid sequence selected from the group consisting of the SEQ ID NO: 41, SEQ ID NO: 42 and SEQ ID NO: 43.
3. The antibody of claim 1 , wherein said variable heavy (VH) region comprises the amino acid sequence selected from the group consisting of the SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38.
4. The antibody of claim 1 , wherein the antibody does not activate CD47 upon binding.
5. The antibody of claim 4 , wherein the antibody is a humanized monoclonal antibody.
6. The antibody of claim 4 , wherein the antibody is a chimeric antibody.
7. A pharmaceutical composition comprising an antibody set forth in claim 1 .
8. A pharmaceutical composition comprising an antibody set forth in claim 1 , and a pharmaceutically acceptable excipient.